Gala awards for innovators
19 August 2009
HRH The Prince Philip Duke of Edinburgh has presented awards to two members of IGMM staff at a gala dinner.
The University of Edinburgh's Chancellor’s Awards were made in the Palace of Holyroodhouse in August.
Professors Harry Campbell and Malcolm Dunlop, of the Institute of Genetics and Molecular Medicine, were presented jointly with an award in recognition of their internationally-recognised research.
They have revolutionised medical understanding of genetic susceptibility to colorectal cancer, a major cause of death worldwide.
The impact of their research will be reflected in screening, disease prevention, disease stratification and personalised treatment.
The awards, now in their fifth year, are presented in recognition of innovation, relevance, creativity and personal dedication.
The prizes, crafted in glass, are the work of Elin Isaksson, Artist in Residence at the Edinburgh College of Art.
Related Links
Professor Malcolm Dunlop
(MRC Human Genetics Unit, Research pages)
Professor Malcolm Dunlop
(Edinburgh Cancer Research Centre, Research pages)
The Institute of Genetics and Molecular Medicine (IGMM)
Professor Harry Campbell: Professor of Genetic Epidemiology and Public Health
Osteoporosis and coeliac disease link
9 October 2009
People with coeliac disease may develop osteoporosis because their immune system attacks their bone tissue, a new study has shown.
It is the first time an autoimmune response - a condition whereby the body can attack itself - has been shown to cause damage to bones directly.
IGMM researchers studied a protein called osteoprotegerin (OPG) in people with coeliac disease - a digestive condition that affects 1 in 100 people.
In healthy people, OPG plays a crucial role in maintaining bone health by controlling the rate at which bone tissue is removed.
The latest research shows that 20 per cent of coeliac patients produce antibodies that attack the OPG protein and stop it working properly. This results in rapid bone destruction and severe osteoporosis.
It was previously thought that osteoporosis - a known complication of coeliac disease - develops in coeliac patients because they cannot properly absorb calcium and vitamin D from their diet. Both nutrients are essential for healthy bone development.
The team found that although this new form of osteoporosis did not respond to calcium and vitamin D supplements, it can be easily treated with drugs that prevent bone loss. The research is published in the New England Journal of Medicine.
Professor Stuart Ralston, of the Institute of Genetics and Molecular Medicine, who led the team, said: “This is a very exciting step forward. Not only have we discovered a new reason to explain why osteoporosis occurs in coeliac disease, but we have also found that it responds very well to drugs that prevent bone tissue removal. Testing for these antibodies could make a real and important difference to the lives of people with coeliac disease by alerting us to the risk of osteoporosis and helping us find the correct treatment for them.”
Related Links
Professor Stuart Ralston: Molecular Medicine Centre,
The University of Edinburgh
